PANACEA BIO CHEM · MOLECULAR REPAIR RESEARCH
Can accumulated protein damage be enzymatically repaired?
The emergence of CMLase has changed a long-standing scientific assumption. Nε-carboxymethyl-lysine, known as CML, is a stable advanced glycation modification that can accumulate on long-lived proteins. Recent research demonstrated that an engineered enzyme can recognise this modification and convert the affected residue back to lysine under controlled experimental conditions. At Panacea Bio Chem, Bogdan Dicoias is investigating what this principle could mean for the wider future of enzymatic protein repair, molecular longevity, formulation science, biochemical stabilisation and targeted delivery.
An active independent research programme of Panacea Bio Chem Ltd, led by Bogdan Dicoias.
The original CrGO-897/CMLase enzyme was reported by external researchers. Panacea Bio Chem’s work represents an independent research direction arising from this scientific breakthrough.
WHAT IS CMLASE?
A new-to-nature enzyme for protein deglycation
CMLase is the name used for an engineered enzyme designed to recognise Nε-carboxymethyl-lysine modifications located on proteins. The reported research enzyme, CrGO-897, was developed from a glycine-oxidase scaffold through computational design, screening and directed evolution. Under controlled laboratory conditions, the enzyme was shown to convert protein-associated CML back into lysine. This represents a significant proof of concept: a stable form of accumulated protein chemical damage can be directly targeted through engineered enzymatic chemistry.
CMLase reverses one specific chemical modification. It is not currently shown to reverse every AGE, every protein cross-link or ageing as a whole.
Bogdan Dicoias — Panacea Bio Chem Ltd
THE RESEARCHER
Bogdan Dicoias on the future of enzymatic protein repair
CMLase changes the scientific question completely. A stable chemical lesion accumulated on a protein no longer has to be viewed only as permanent damage. It can now be investigated as a possible enzymatic repair target.
At Panacea Bio Chem, we are exploring how this principle may be extended through enzyme engineering, formulation science, biochemical stabilisation, preservation and targeted delivery.
This field is only beginning. I expect the Panacea research programme to produce important findings and new technological directions in the near future.
WHAT IS CML?
A persistent chemical modification of lysine
CML — Nε-carboxymethyl-lysine — is an advanced glycation end-product (AGE). It forms non-enzymatically, without any enzyme directing the reaction, and it can accumulate on long-lived proteins over time.
CML is associated with the chemical ageing of collagen and the extracellular matrix, and it can act as a signal through RAGE, the receptor for advanced glycation end-products. It is chemically different from glucosepane, another AGE cross-link, and it is not simply glucose temporarily attached to a protein — it is a stable, rearranged modification.
This is why prevention and removal are different problems: strategies that reduce new glycation do not remove the CML that has already accumulated.
| Approach | Target | Timing | Purpose |
|---|---|---|---|
| Carbonyl control | Reactive precursors | Before damage | Reduce new glycation |
| Glycation inhibition | Early reactions | During formation | Slow accumulation |
| Enzymatic deglycation | Existing CML | After formation | Restore lysine |
THE SCIENTIFIC SHIFT
From damage prevention to molecular repair
Most glycation strategies attempt to prevent new damage. CMLase introduces a different possibility: directly recognising and repairing a modification after it has already accumulated. For Panacea Bio Chem, this opens a broader research direction involving:
- engineered molecular repair systems
- enzyme formulation
- enzyme stabilisation
- protection against oxidation
- preservation of catalytic activity
- controlled delivery
- low-temperature formulation
- oxygen management
- targeted biochemical intervention
- compatibility with long-lived extracellular proteins
The future may not be limited to slowing molecular damage. It may include repairing it.
RESEARCH WATCH
Protein Repair & Deglycation Watch
Last updated: 2026-08-23
2026-08-21
Caffeic acid phenethyl ester derivatives inhibit glyoxalase I activity and induce cell death in cultured cancer cell lines
protein repair & deglycation watch
1. Bioorg Med Chem Lett. 2026 Aug 21:130762. doi: 10.1016/j.bmcl.2026.130762. Online ahead of print. Caffeic acid phenethyl ester derivatives inhibit glyoxalase I activity and induce cell death in cultured cancer cell lines.
Peer-reviewed study
2026-08-17
Oleanolic Acid-Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial
protein repair & deglycation watch
1. Diabetes Obes Metab. 2026 Aug 17. doi: 10.1111/dom.71206. Online ahead of print. Oleanolic Acid-Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial.
Peer-reviewed study
2026-08-17
Mutation and oxidation of Cys46 and Cys53 allosterically modulate the glyoxalase and esterase activities of DJ-1
protein repair & deglycation watch
1. Int J Biol Macromol. 2026 Aug 17;380:154089. doi: 10.1016/j.ijbiomac.2026.154089. Online ahead of print. Mutation and oxidation of Cys46 and Cys53 allosterically modulate the glyoxalase and esterase activities of DJ-1. Xia Y(1), He X(2), Zhang Y(2), Wang Z(2), Hu R(1), Li Y(1), Zhu J(3), Yang Y(4), Liu M(1).
Peer-reviewed study
International journal of biological macromolecules via PubMed ↗
2026-08-13
Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer
protein repair & deglycation watch
1. J Immunother Cancer. 2026 Aug 13;14(8):e014841. doi: 10.1136/jitc-2026-014841. Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer.
Peer-reviewed study
THE PANACEA TECHNOLOGY UNIVERSE
Twenty-four technologies, each the leader of its class
Proprietary Panacea Bio Chem Ltd technologies, invented by Bogdan Dicoias — what each one does, and why it leads its class.
Lyoprester®
The only dual-chamber cartridge that is autoreconstitution-enabled, vacuum-sealed and argon-fillback.
Cake and liquid never meet until the moment of use — no contamination, no transfer, no compromise. A conventional vial wets only the surface; the Lyoprester carries Peptourbillon loads approaching 200 mg.
Lyoprester SS: screw a needle, inject, throw.
P-EARLs™
Panacea-Engineered Aseptic Reconstitution Liquid(s) — each tuned to the peptide it wakes.
Bacteriostatic water is a fine diluent and nothing more. A P-EARL is engineered around the peptide’s pI-aggregation behaviour and its Met/Cys/His/Trp oxidation profile.
GHK-Cu: a chelation-withholding liquid design, not generic water.
Peptourbillon™
The layered peptide formulation architecture — single- or multi-layer, never a blend.
Each active keeps its own lyophilised phase: near-eutectic layering, ultrasound freezing, −80 °C stack, RF-assisted drying. Chemistries that would destroy each other in a blend arrive as neighbours, not mixtures.
Dual-layer cakes: one active below, a second above — one chamber, zero contact.
RF Tunnel™
The RF-formed central channel through the cake.
Two wetting fronts instead of one — reconstitution solved by geometry, not surfactants.
The hard cases: heavy-loaded, lipidated (GLP-class) and gel-blocking APIs.
TgShift™
Raises the cake’s glass-transition temperature with RF — instead of chilling below it.
Drying runs warmer and faster while the structure stays below collapse — cycles shorten from days toward hours.
Reference points: trehalose ≈ −29 °C, sucrose ≈ −32 °C — shifted upward, not endured.
Cryolapse™
Cryogenic pressure collapse — and the machine that pushes plungers and crimps.
Cryopumping to −110 °C pulls cycles from ~13 hours toward ~4, surfactant-free; the same machine enables ElimiVoid, IncreSure and Cryoviscous.
A 3× time compression on a real lyo cycle, without a surfactant in sight.
LyoLevit™
The cake levitates and spins in high orbit — driven by ultrasound and RF.
Zero-contact processing: 99% reproducibility, 89% energy reduction, a 4–6× gain in sublimation surface.
No shelf contact means no hot spots — uniformity is the mechanism, not the hope.
Lyochrysalis™
The integrated chamber housing the whole drying stack.
It finishes cold — it never cooks the peptide. No +40/+60 °C secondary bake, so binding affinity and bioavailability survive.
TgShift + LyoLevit + Cryolapse + DiastolVAC + S3Pulse in one housing.
S3Pulse™
The control brain for every piece of Panacea hardware.
Sixteen relay channels, three dipped product probes as the authority, Cryo-Triad event detection and a Kv-learning adaptive ramp — the only platform that enables every other technology.
14,909 automated contract tests stand behind the control law.
Liquiprester™
The single-liquid cartridge engineered so multiple peptide APIs coexist in one shared vehicle.
The glass may vary, the dose must not: a fixed plunger datum with ElimiVoid, bore-variance self-counterbalancing, and IncreSure verification per increment.
Dose accuracy that survives manufacturing tolerance — by design, not inspection.
Syntheseract™
Continuous-flow peptide synthesis in a special, very fast and economical way.
Batch synthesis is “more product, blindly”; Syntheseract is scalable production, observed — 64 positions, 128+ addresses, and a Digital Batch DNA for every run.
Sprint, Economy and Fortress modes — the economics chosen per peptide, not per habit.
CFSPPS™
Continuous-flow solid-phase peptide synthesis, written as its own category.
Setpoint ≠ experience: in flow, every residue addition is observed and repeatable instead of assumed.
The category reference the field reads before arguing.
OxyDeplete™
Degassing plus no-headspace doctrine — the oxygen-starved seal.
Trapped oxygen does not escape, it reacts. Remove it first and stability extends into years instead of months.
Air seal vs oxygen-starved seal: the comparison the oxidation model is built on.
ArgonLock™
The final inert-atmosphere lock under argon.
After drying, the cake is backfilled and sealed under argon — the principle that protects welding arcs, wine cellars and the Charters of Freedom, applied to peptides.
Air vs vacuum-only vs ArgonLock — the three-face comparison, settled.
RedoxVault™
Separation, not merely suppression — redox isolation in lipid micro-reservoirs.
A few ppb of iron can outweigh grams of antioxidant; the vault removes the catalyst from reach, with depot and delayed-release microsphere formats on top.
A strongroom at the scale of a droplet — the ferritin principle, engineered.
PleniDose™
The shared filling gantry — one machine filling both the dual-chamber Lyoprester and the liquid Liquiprester.
Only the rods holder changes between the two product lines; the rear-plunger datum is fixed and pen-compatible. The glass may vary — the dose must not.
Known inside the machine software as the Lyochrysalis Gantry: one gantry, two product lines.
IncreSure™
The dose-metrology layer — verified API per pen increment.
The printed “60 IU” dial figure is not the API in the cartridge and not the volume per click. IncreSure characterises seven real pen parameters instead of trusting the label — a Cryolapse-enabled discipline.
Piston travel per increment: measured, never assumed.
ElimiVoid™
Front-void elimination without touching the metered dose.
It removes the compressible air pocket ahead of the dose — without moving the rear plunger, without withdrawing API, without changing the delivered increment. A Cryolapse-enabled operation.
The completion liquid is API-free, buffer-free and engineered to stay out of the way.
Cryoviscous™
The characterised cold, high-viscosity, low-mobility conditioning state.
The formulation is held temporarily still — strongly flow-restricted — for precision cartridge filling, then recovers within acceptance criteria on controlled warming.
A processing state, not merely “cold liquid”.
Vana Machine™
Vacuum Assisted Needle Accessory — vacuum conditioning and plunger-locking for the cartridge.
It prevents air gaps and plunger drift, landing the target vacuum inside the Lyopresters and keeping it there until the moment of use.
The machine that vacuum-conditions the cartridge before it ever meets a needle.
EZnject™
The disposable auto-injector pen built around the Lyoprester.
One twist activates autoreconstitution — the P-EARLs is drawn into the peptide chamber at the septa. A hundred indexed 0.1 mL doses with lab-grade accuracy; ships with 31G/5 mm needles and a Peptourbillon pre-loaded.
One twist — no vial, no syringe, no transfer.
Dicoias Ψ
The computed-chemistry advisory — every substance reduced to a vector across physical, electronic and formulation space.
Structure-guided descriptors first, laboratory work second: the Ψ advisory ranks excipients, vehicles and layer candidates before the first bench run — the selection layer behind Panacea formulation decisions.
The molecule’s structure reads the shortlist before the bench hears it.
SealoPrester™
Aseptic Cartridge Closure System — Seal o’ Precision + Sterility.
It mechanically seals the caps of vacuum-charged, argon-locked cartridges that arrive held together by vacuum alone — one wrong move and the cartridge self-reconstitutes or loses its atmosphere. In cahoots with VANA, it gives birth to the Lyoprester.
The machine that turns a banal dual-chamber cartridge into a Lyoprester.
Peptidic Liquid
The peptide formulation in solution — the active plus its buffers, cryoprotectants, lyoprotectants and scaffolders.
A peptide is only as good as the liquid it lives in: this is the formulation that decides whether a dose survives freezing, drying, storage and the journey back to solution. Designed with Dicoias Ψ.
The liquid every Lyoprester is born from and every Liquiprester keeps.
The molecular-repair era is beginning
CMLase has demonstrated that a stable chemical mark accumulated on proteins can become an engineered enzymatic target. Panacea Bio Chem is now investigating where that principle can lead.